

INTERNATIONAL SEARCH REPORT

International application No.

PCT/JP2004/005065

A. CLASSIFICATION OF SUBJECT MATTER

Int.Cl⁷ A61K45/00, 31/502, A61P3/10, 3/04, 3/06, 9/00, 9/10, 9/04,
43/00//C07D403/04, 237/26

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

Int.Cl⁷ A61K45/00, 31/502, A61P3/10, 3/04, 3/06, 9/00, 9/10, 9/04,
43/00, C07D403/04, 237/26

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)
REGISTRY (STN), CAPLUS (STN)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	JP 10-109936 A (Mitsubishi Chemical Corp.), 28 April, 1998 (28.04.98), Full text; particularly, Claims; examples (Family: none)	1-8
X	JP 8-034734 A (Mitsubishi Chemical Corp.), 06 February, 1996 (06.02.96), Full text; particularly, Claims; examples & EP 682947 A1 & US 5643911 A & CN 1116526 A & CA 2149691 A	1-8
X	JP 6-135938 A (Mitsubishi Chemical Corp.), 17 May, 1994 (17.05.94), Full text; particularly, Claims; examples & EP 534443 A1 & US 5324727 A & CA 2078699 A	1-8

☒ Further documents are listed in the continuation of Box C.

☐ See patent family annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"Q" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search
13 July, 2004 (13.07.04)

Date of mailing of the international search report
17 August, 2004 (17.08.04)

Name and mailing address of the ISA/
Japanese Patent Office

Authorized officer

Facsimile No.

Telephone No.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/JP2004/005065

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	JP 4-211666 A (Mitsubishi Chemical Corp.), 03 August, 1992 (03.08.92), Full text; particularly, Claims; examples & EP 449203 A1 & US 5089494 A & CA 2039258 A	1-8
X	JP 2-129180 A (Morishita Pharmaceutical Co., Ltd.), 17 May, 1990 (17.05.90), Full text; particularly, Claims; examples (Family: none)	1-8
A	JP 62-228067 A (Dainippon Pharmaceutical Co., Ltd.), 06 October, 1987 (06.10.87), Full text; particularly, Claims; examples (Family: none)	1-8

INTERNATIONAL SEARCH REPORT

International application No.

PCT/JP2004/005065

<Subject of search>

Claims 1 to 8 relate to an NAD(P)H oxidase hyperfunction inhibitor containing, as the active ingredient, a compound defined by a desired property "substantially not inhibiting NADPH oxidase originating in leukocytes but inhibiting NAD(P)H oxidase originating in tissues other than leukocytes" or a medicinal composition for diseases caused by the hyperfunction of NAD(P)H oxidase. It is recognized that only specific small part of the claimed compounds are supported by the description in the meaning within PCT Article 6 and disclosed therein in the meaning within PCT Article 5.

Even though the common technical knowledge at the point of the application is considered, the scope of compounds having the above property cannot be specified.

Such being the case, the search was made mainly on the compounds A to H which is specifically illustrated as having the above property in the description (in the description, the compounds A and B alone are specifically shown as not inhibiting the leukocyte NADPH oxidase function).